TY  - GEN
AU  - Cainap,Calin
AU  - Qin,Shukui
AU  - Huang,Wen-Tsung
AU  - Chung,Ik Joo
AU  - Pan,Hongming
AU  - Cheng,Ying
AU  - Kudo,Masatoshi
AU  - Kang,Yoon-Koo
AU  - Chen,Pei-Jer
AU  - Toh,Han-Chong
AU  - Gorbunova,Vera
AU  - Eskens,Ferry A L M
AU  - Qian,Jiang
AU  - McKee,Mark D
AU  - Ricker,Justin L
AU  - Carlson,Dawn M
AU  - El-Nowiem,Saied
TI  - Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial
SN  - 1527-7755
PY  - 2015///0316
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Carcinoma, Hepatocellular
KW  - drug therapy
KW  - Drug Administration Schedule
KW  - Female
KW  - Hand-Foot Syndrome
KW  - etiology
KW  - Humans
KW  - Hypertension
KW  - chemically induced
KW  - Indazoles
KW  - Kaplan-Meier Estimate
KW  - Liver Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Niacinamide
KW  - Odds Ratio
KW  - Phenylurea Compounds
KW  - Protein Kinase Inhibitors
KW  - Receptor Protein-Tyrosine Kinases
KW  - antagonists & inhibitors
KW  - Risk Factors
KW  - Sorafenib
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2013.54.3298
ER  -